Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Croce

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Journal of Health Care Finance|February 15, 2012
Introduction of concept of cost centre management in a public hospital in South AfricaDebashis Basu, Davide Croce, Emanuele Porazzi, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 14, 2017
Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trialUmberto Restelli, Massimiliano Fabbiani, Simona Di Giambenedetto, et al.
Global & Regional Health Technology Assessment|January 9, 2026
Health technology assessment of an automated unit-dose drug distribution system in a high-specialization national referral hospital of the Italian National Health ServiceDavide Croce, Francesco De Nardo, Francesca Convenga, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 11, 2017
Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trialUmberto Restelli, Massimiliano Fabbiani, Simona Di Giambenedetto, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 24, 2016
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in ItalyUmberto Restelli, Alfredo Alberti, Adriano Lazzarin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 25, 2020
Cost of illness of Primary Biliary Cholangitis - a population-based studyAlessio Gerussi, Umberto Restelli, Davide Croce, et al.
Therapeutics and Clinical Risk Management|July 20, 2017
Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patientsUmberto Restelli, Giuliano Rizzardini, Andrea Antinori, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 31, 2016
HCV novel therapeutic regimens in Wonderland: A budget impact analysis in the Lombardy RegionElisabetta Garagiola, Lucrezia Ferrario, Davide Croce, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 28, 2017
Economic and organizational sustainability of a negative-pressure portable device for the prevention of surgical-site complicationsEmanuela Foglia, Lucrezia Ferrario, Elisabetta Garagiola, et al.
Acta Tropica|December 8, 2009
Cost-effectiveness of a successful schistosomiasis control programme in Cambodia (1995-2006)Davide Croce, Emanuele Porazzi, Emanuela Foglia, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Journal of Health Care Finance|February 15, 2012
Introduction of concept of cost centre management in a public hospital in South AfricaDebashis Basu, Davide Croce, Emanuele Porazzi, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 14, 2017
Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trialUmberto Restelli, Massimiliano Fabbiani, Simona Di Giambenedetto, et al.
Global & Regional Health Technology Assessment|January 9, 2026
Health technology assessment of an automated unit-dose drug distribution system in a high-specialization national referral hospital of the Italian National Health ServiceDavide Croce, Francesco De Nardo, Francesca Convenga, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 11, 2017
Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trialUmberto Restelli, Massimiliano Fabbiani, Simona Di Giambenedetto, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 24, 2016
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in ItalyUmberto Restelli, Alfredo Alberti, Adriano Lazzarin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 25, 2020
Cost of illness of Primary Biliary Cholangitis - a population-based studyAlessio Gerussi, Umberto Restelli, Davide Croce, et al.
Therapeutics and Clinical Risk Management|July 20, 2017
Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patientsUmberto Restelli, Giuliano Rizzardini, Andrea Antinori, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 31, 2016
HCV novel therapeutic regimens in Wonderland: A budget impact analysis in the Lombardy RegionElisabetta Garagiola, Lucrezia Ferrario, Davide Croce, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 28, 2017
Economic and organizational sustainability of a negative-pressure portable device for the prevention of surgical-site complicationsEmanuela Foglia, Lucrezia Ferrario, Elisabetta Garagiola, et al.
Acta Tropica|December 8, 2009
Cost-effectiveness of a successful schistosomiasis control programme in Cambodia (1995-2006)Davide Croce, Emanuele Porazzi, Emanuela Foglia, et al.
Pageof 6